News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
528,455 Results
Type
Article (33579)
Company Profile (178)
Press Release (494698)
Section
Business (154873)
Career Advice (729)
Deals (25249)
Drug Delivery (60)
Drug Development (59561)
Employer Resources (78)
FDA (14223)
Job Trends (11865)
News (259369)
Policy (24118)
Tag
Academia (2284)
Alliances (43166)
Alzheimer's disease (906)
Approvals (14167)
Artificial intelligence (122)
Bankruptcy (204)
Best Places to Work (9600)
Biotechnology (132)
Breast cancer (91)
Cancer (734)
Cardiovascular disease (70)
Career advice (655)
Cell therapy (167)
Clinical research (47495)
Collaboration (303)
Compensation (73)
COVID-19 (1945)
C-suite (71)
Data (738)
Diabetes (103)
Diagnostics (5579)
Earnings (53211)
Employer resources (70)
Events (74725)
Executive appointments (210)
FDA (14622)
Funding (234)
Gene therapy (116)
GLP-1 (405)
Government (3407)
Healthcare (15457)
Infectious disease (2004)
Inflammatory bowel disease (80)
Interviews (74)
IPO (10803)
Job creations (2559)
Job search strategy (591)
Layoffs (224)
Legal (4926)
Lung cancer (132)
Manufacturing (108)
Medical device (13811)
Medtech (13816)
Mergers & acquisitions (14504)
Metabolic disorders (279)
Neuroscience (1080)
NextGen Class of 2024 (5388)
Non-profit (3386)
Northern California (902)
Obesity (157)
Opinion (105)
Patents (80)
People (46599)
Phase I (14641)
Phase II (20764)
Phase III (16045)
Pipeline (166)
Postmarket research (1805)
Preclinical (5742)
Radiopharmaceuticals (204)
Rare diseases (130)
Real estate (4605)
Regulatory (16746)
Research institute (2070)
Resumes & cover letters (99)
Southern California (815)
Startups (3198)
United States (9033)
Vaccines (416)
Weight loss (119)
Date
Today (171)
Last 7 days (645)
Last 30 days (2302)
Last 365 days (28291)
2024 (24014)
2023 (31914)
2022 (42306)
2021 (45751)
2020 (44563)
2019 (39091)
2018 (29738)
2017 (26811)
2016 (25741)
2015 (30022)
2014 (22806)
2013 (19194)
2012 (20786)
2011 (21274)
2010 (19632)
Location
Africa (512)
Arizona (138)
Asia (33082)
Australia (5609)
California (2032)
Canada (974)
China (176)
Colorado (94)
Connecticut (100)
Europe (69935)
Florida (335)
Georgia (88)
Illinois (250)
Indiana (142)
Kansas (93)
Maryland (464)
Massachusetts (1517)
Michigan (147)
Minnesota (209)
New Jersey (673)
New York (634)
North Carolina (546)
Northern California (902)
Ohio (109)
Pennsylvania (535)
South America (768)
Southern California (815)
Texas (302)
Utah (69)
Washington State (264)
528,455 Results for "helius medical technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
News
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
October 18, 2024
·
1 min read
Pharm Country
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference 2024
Helius Medical Technologies, Inc. announced that it will participate in the Spring MicroCap Rodeo Conference to be held on Thursday, June 6th in NYC.
May 31, 2024
·
6 min read
Business
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced results for the quarter ended March 31, 2024.
May 13, 2024
·
10 min read
Pharm Country
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
Helius Medical Technologies, Inc. announced the completion of site participation enrollment for its stroke registrational program in the U.S. with the addition of REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions.
June 17, 2024
·
10 min read
Pharm Country
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
Helius Medical Technologies, Inc. today announced the expansion of its clinical development program for the broadening of the labeling of its marketed PoNS device.
April 24, 2024
·
7 min read
Press Releases
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study
September 30, 2024
·
10 min read
Business
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
Helius Medical Technologies, Inc. today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes.
May 10, 2024
·
2 min read
Pharm Country
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier
Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced the first third-party reimbursement from a major insurance carrier for the Company’s Portable Neuromodulation Stimulator device.
May 29, 2024
·
5 min read
Pharm Country
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
Helius Medical Technologies, Inc. today announced the initiation of an open-label study for its registrational program in stroke.
March 12, 2024
·
7 min read
Pharm Country
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
Helius Medical Technologies, Inc. announced the pricing of a public offering of 804,999 shares of its Class A common stock and 2,047,222 Pre-Funded Warrants, each to purchase one share of Common Stock, together with accompanying Series A and Series B warrants to purchase up to an aggregate of 5,704,442 shares of Common Stock.
May 6, 2024
·
4 min read
1 of 52,846
Next
